The U.S. Food and Drug Administration (FDA) is expected to decide by the end of February whether or not to approve ciltacabtagene autoleucel, known as cilta-cel, an investigational CAR T-cell therapy for the treatment of relapsed or refractory multiple myeloma. The FDA extended its expected decision date to allow sufficient time to review information about an updated analytical method — which the FDA had requested and was recently submitted by the investigational therapy’s co-developers Legend…
You must be logged in to read/download the full post.
The post FDA Expects Decision on Cilta-cel Approval by February 2022 appeared first on BioNewsFeeds.